Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA Phase 2 Data Anticipated in Second Quarter of 2012

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service26 times read : Adjust font size: Decrease font Enlarge font
image

Idera Pharmaceuticals entered into its worldwide licensing and collaboration agreement with Merck KGaA,

Read this article...



Post your comment comment Comments (0 posted)

More News

copyright